All In Biotech

Drug Trial Radar · NCT03347279

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

Last checked: Nov 20, 2026Latest source record: Nov 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,061 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,061

Actual

Start

Nov 23, 2017

Primary completion

Sep 8, 2020

Study completion Nov 12, 2020

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Nov 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

Conditions

  • Asthma

Interventions

  • Experimental: TezepelumabBiological

    Tezepelumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled AsthmaTime frame: From randomisation to Study Week 52.
  2. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uLTime frame: From randomisation to Study Week 52.

Locations

289 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Foley, Alabama

  • Research Site

    Gilbert, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Encinitas, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Mission Viejo, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Palm Desert, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Westminster, California

  • Research Site

    Denver, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Celebration, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Panama City, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Sebring, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Fayetteville, Georgia

  • Research Site

    Gainesville, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Michigan City, Indiana

  • Research Site

    Fort Mitchell, Kentucky

  • Research Site

    Louisville, Kentucky

Showing 40 of 289 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.